Halle-Smith James M, Pearce Hayden, Nicol Samantha, Hall Lewis A, Powell-Brett Sarah F, Beggs Andrew D, Iqbal Tariq, Moss Paul, Roberts Keith J
Hepatobiliary and Pancreatic Surgery Unit, Queen Elizabeth Hospital Birmingham, Birmingham B15 2GW, UK.
Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, UK.
Cancers (Basel). 2024 Feb 29;16(5):996. doi: 10.3390/cancers16050996.
The systemic and local immunosuppression exhibited by pancreatic ductal adenocarcinoma (PDAC) contributes significantly to its aggressive nature. There is a need for a greater understanding of the mechanisms behind this profound immune evasion, which makes it one of the most challenging malignancies to treat and thus one of the leading causes of cancer death worldwide. The gut microbiome is now thought to be the largest immune organ in the body and has been shown to play an important role in multiple immune-mediated diseases. By summarizing the current literature, this review examines the mechanisms by which the gut microbiome may modulate the immune response to PDAC. Evidence suggests that the gut microbiome can alter immune cell populations both in the peripheral blood and within the tumour itself in PDAC patients. In addition, evidence suggests that the gut microbiome influences the composition of the PDAC tumour microbiome, which exerts a local effect on PDAC tumour immune infiltration. Put together, this promotes the gut microbiome as a promising route for future therapies to improve immune responses in PDAC patients.
Biomedicines. 2020-12-3
Cancers (Basel). 2022-9-15
Cytokine Growth Factor Rev. 2023
Cancers (Basel). 2021-7-27
World J Gastrointest Oncol. 2022-7-15
Cell Rep Med. 2023-1-17
Front Oncol. 2022-11-29